Grants and Contributions:
Title:
Somatostatin 2 Receptor (SSTR2) Antagonists: Efficacy in managing Type 2 Diabetes
Agreement Number:
952208
Agreement Value:
$550,000.00
Agreement Date:
Jun 1, 2020 - Mar 31, 2022
Description:
The firm is developing a first-in-class therapeutic agent to prevent dangerously low blood sugar in insulin dependent Type 1 Diabetics. This project aims to demonstrate the same effect in Type 2 diabetics and prepare for a line extension to the Type 1 program already underway.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Vancouver, British Columbia, CA V6T 1Z3
Reference Number:
172-2020-2021-Q1-952208
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
821538386
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The total amended value is 50,000 dollars.
Amendment Date
Mar 1, 2022
Recipient's Legal Name:
Zucara Therapeutics Inc.
Federal Riding Name:
Vancouver Quadra
Federal Riding Number:
59039
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710
Amendments: